About Ironwood Pharmaceuticals (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-19.83
Forward P/E Ratio-25.61
Sales & Book Value
Annual Sales$298.28 million
Price / Sales9.39
Price / CashN/A
Book Value$0.07 per share
Price / Book263.43
EPS (Most Recent Fiscal Year)($0.93)
Return on Equity-2,073.20%
Return on Assets-20.90%
Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.06. The biotechnology company earned $69.16 million during the quarter, compared to the consensus estimate of $78.65 million. Ironwood Pharmaceuticals had a negative net margin of 34.12% and a negative return on equity of 2,073.20%. The firm's quarterly revenue was up 32.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) EPS. View Ironwood Pharmaceuticals' Earnings History.
When is Ironwood Pharmaceuticals' next earnings date?
What price target have analysts set for IRWD?
9 equities research analysts have issued twelve-month price objectives for Ironwood Pharmaceuticals' shares. Their predictions range from $13.00 to $25.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $19.4444 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.
Are investors shorting Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totalling 18,814,070 shares, a decline of 12.2% from the April 30th total of 21,438,253 shares. Based on an average daily trading volume, of 1,695,797 shares, the short-interest ratio is currently 11.1 days. Approximately 13.7% of the shares of the company are sold short.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), BeiGene (BGNE), Genmab A/S (GNMSF), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO) and Loxo Oncology (LOXO).
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 54)
- Dr. Mark G. Currie, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 63)
- Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 48)
- Mr. Thomas A. McCourt, Sr. VP of Marketing & Sales and Chief Commercial Officer (Age 61)
- Mr. Brian M. Cali Ph.D., Co-Founder and Sr. VP of R&D Strategy & External Innovation
Has Ironwood Pharmaceuticals been receiving favorable news coverage?
News coverage about IRWD stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Ironwood Pharmaceuticals' major shareholders?
Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (3.65%), OppenheimerFunds Inc. (1.70%), Northern Trust Corp (1.03%), Loomis Sayles & Co. L P (1.01%), Sector Gamma AS (0.74%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.
Which institutional investors are selling Ironwood Pharmaceuticals stock?
IRWD stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Artal Group S.A., State of Wisconsin Investment Board, Barclays PLC, Sector Gamma AS, Loomis Sayles & Co. L P, California Public Employees Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie and Peter M Hecht. View Insider Buying and Selling for Ironwood Pharmaceuticals.
Which institutional investors are buying Ironwood Pharmaceuticals stock?
IRWD stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, OppenheimerFunds Inc., UBS Group AG, Engineers Gate Manager LP, Point72 Asset Management L.P., Trexquant Investment LP, Schwab Charles Investment Management Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.
How do I buy shares of Ironwood Pharmaceuticals?
Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
One share of IRWD stock can currently be purchased for approximately $18.44.
How big of a company is Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals has a market capitalization of $2.80 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.
How can I contact Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]
MarketBeat Community Rating for Ironwood Pharmaceuticals (IRWD)MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.